Michael Cherny
Stock Analyst at Leerink Partners
(4.40)
# 326
Out of 5,148 analysts
119
Total ratings
61.36%
Success rate
15.59%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $5.16 | +6.59% | 2 | Feb 26, 2026 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $20 → $18 | $16.48 | +6.19% | 11 | Feb 24, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $81.37 | +6.92% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $2.35 | +17.02% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $14.31 | +18.80% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $457.47 | +6.02% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $81.66 | +16.34% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $45.85 | +4.69% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $7.05 | +84.40% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $210.25 | -0.12% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $785 → $850 | $990.95 | -14.22% | 15 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $229.88 | -19.09% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $17.60 | +59.09% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.16 | +158.62% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $29.44 | -21.88% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $25.70 | +250.19% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $189.02 | +48.13% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $174.27 | +42.31% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $108.27 | +135.52% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $372.65 | -26.20% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $286.47 | -9.24% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.17 | +268.66% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.35 | +3,788.89% | 2 | Jan 5, 2022 |
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $5.16
Upside: +6.59%
Hims & Hers Health
Feb 24, 2026
Maintains: Market Perform
Price Target: $20 → $18
Current: $16.48
Upside: +6.19%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $81.37
Upside: +6.92%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $2.35
Upside: +17.02%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $14.31
Upside: +18.80%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $457.47
Upside: +6.02%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $81.66
Upside: +16.34%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.85
Upside: +4.69%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $7.05
Upside: +84.40%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $210.25
Upside: -0.12%
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $990.95
Upside: -14.22%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $229.88
Upside: -19.09%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $17.60
Upside: +59.09%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.16
Upside: +158.62%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $29.44
Upside: -21.88%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $25.70
Upside: +250.19%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $189.02
Upside: +48.13%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $174.27
Upside: +42.31%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $108.27
Upside: +135.52%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $372.65
Upside: -26.20%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $286.47
Upside: -9.24%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.17
Upside: +268.66%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.35
Upside: +3,788.89%